ASTON, Pa., Dec. 1 /PRNewswire/ -- Innocoll, Inc., a specialty pharmaceutical company focused on the development and supply of novel treatments for pain and infection, today announced the establishment of an R&D and Manufacturing Operations facility in Roscommon Town with the support of IDA Ireland, the investment and development agency of Ireland. The company also announced the creation of a European Sales and Marketing division, which will be headquartered in Athlone.
The facility, located in Roscommon Town, was formerly owned by Elan Corporation and will provide Innocoll with extensive R&D capacity, clean rooms and GMP manufacturing capabilities at both laboratory and commercial scale. Up to 60 new jobs will be created over four years, 70% of which will require third-level qualifications.
Innocoll Pharmaceuticals will establish its European Headquarters in Athlone, creating up to 16 new jobs based in Ireland alone. The division will sell products developed by Innocoll Technologies and through product acquisitions which have an overall strategic fit with Innocoll Pharmaceuticals' core product portfolio. Innocoll Pharmaceuticals will commence marketing of its first product in Europe in January 2005.
Innocoll's senior management team is headed by Dr. Michael Myers, 43, President and Chief Executive Officer, who served formerly as President of the Drug Delivery Division at West Pharmaceutical Services. Dr. Myers has over 16 years' experience in the pharmaceutical industry and has held senior executive positions with Flamel Technologies, Fuisz Technologies, and Elan Corporation. The senior management team includes Denise Carter, 36, President, Innocoll Pharmaceuticals; Joan FitzPatrick, 35, VP Research and Development, Innocoll Technologies; and David Prior, Ph.D., 43, Vice President Business Development, Innocoll Technologies.
Dr. Myers commented, "Expanding our operations into two distinct business divisions represents yet another significant milestone in the transition of Innocoll from a contract manufacturing organization to a fully integrated specialty pharmaceutical company. We hope to recognize significant advantages by establishing both divisions in Ireland. We will have the capacity to rapidly develop, commercialize, and market our exciting product pipeline and the close proximity to several major research centers will provide Innocoll with valuable access to technical and academic resources."
Minister for Enterprise, Trade and Employment, Micheal Martin T.D., welcoming Innocoll to Ireland, said, "These investments are important additions to Ireland's technology sector as healthcare is a valuable and growing market and Innocoll has developed a successful niche in the business. At Roscommon the R&D team will promote interaction with third-level institutions and all new Intellectual Property (IP) developed will reside in Ireland."
About Innocoll, Inc.
Innocoll is a privately held, international specialty pharmaceutical company engaged in the development and commercialization of advanced, differentiated prescription products using its proprietary technology, CollaRx(TM): a collagen-based platform for the targeted delivery of a wide variety of medicines. For more information, please visit http://www.innocoll.com/.
Innocoll, Inc.CONTACT: Melissa Koch, Sr. Director Marketing and Corporate Relations,Innocoll, +1-610-459-4278
Web site: http://www.innocoll.com/
